MX2013013781A - Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina. - Google Patents
Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina.Info
- Publication number
- MX2013013781A MX2013013781A MX2013013781A MX2013013781A MX2013013781A MX 2013013781 A MX2013013781 A MX 2013013781A MX 2013013781 A MX2013013781 A MX 2013013781A MX 2013013781 A MX2013013781 A MX 2013013781A MX 2013013781 A MX2013013781 A MX 2013013781A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- around
- fumarate
- years
- reduced
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 23
- 102000006386 Myelin Proteins Human genes 0.000 title claims abstract description 15
- 108010083674 Myelin Proteins Proteins 0.000 title claims abstract description 15
- 210000005012 myelin Anatomy 0.000 title claims abstract description 15
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims abstract description 142
- 229960004419 dimethyl fumarate Drugs 0.000 claims abstract description 140
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 84
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 84
- 230000003902 lesion Effects 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims description 108
- 229940068196 placebo Drugs 0.000 claims description 66
- 239000000902 placebo Substances 0.000 claims description 66
- 230000009467 reduction Effects 0.000 claims description 44
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 22
- 230000008859 change Effects 0.000 claims description 22
- 230000006378 damage Effects 0.000 claims description 10
- -1 dimethoxy fumarate Chemical group 0.000 claims description 9
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 abstract description 49
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 abstract description 47
- 229940005650 monomethyl fumarate Drugs 0.000 abstract description 7
- 229910052688 Gadolinium Inorganic materials 0.000 abstract description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 14
- 108010072051 Glatiramer Acetate Proteins 0.000 description 12
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 229960003776 glatiramer acetate Drugs 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000005415 magnetization Effects 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 101000916289 Ctenocephalides felis Salivary antigen 1 Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- OEIQOKPNLCRCFM-YBFXNURJSA-N 1-[(E)-(1,3-benzothiazol-2-ylhydrazinylidene)methyl]naphthalen-2-ol Chemical compound Oc1ccc2ccccc2c1\C=N\N=c1\[nH]c2ccccc2s1 OEIQOKPNLCRCFM-YBFXNURJSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101800000789 Protease-polymerase p70 Proteins 0.000 description 1
- 101800000786 Protease-polymerase p76 Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490572P | 2011-05-26 | 2011-05-26 | |
| US201261625624P | 2012-04-17 | 2012-04-17 | |
| PCT/US2012/039721 WO2012162669A1 (en) | 2011-05-26 | 2012-05-25 | Methods of treating multiple sclerosis and preserving and/or increasing myelin content |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013013781A true MX2013013781A (es) | 2014-01-08 |
Family
ID=47217796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013781A MX2013013781A (es) | 2011-05-26 | 2012-05-25 | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140163100A1 (enExample) |
| EP (1) | EP2713724A4 (enExample) |
| JP (1) | JP2014515373A (enExample) |
| KR (1) | KR20140036257A (enExample) |
| CN (1) | CN103732062A (enExample) |
| AU (1) | AU2012258558A1 (enExample) |
| BR (1) | BR112013030169A2 (enExample) |
| CA (1) | CA2836480A1 (enExample) |
| CL (1) | CL2013003358A1 (enExample) |
| CO (1) | CO6811862A2 (enExample) |
| EA (1) | EA201391578A1 (enExample) |
| EC (1) | ECSP13013117A (enExample) |
| IL (1) | IL229448A0 (enExample) |
| MX (1) | MX2013013781A (enExample) |
| PE (1) | PE20141316A1 (enExample) |
| PH (1) | PH12013502443A1 (enExample) |
| SG (1) | SG195049A1 (enExample) |
| WO (1) | WO2012162669A1 (enExample) |
| ZA (1) | ZA201308681B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1663197T3 (da) | 2003-09-09 | 2008-01-07 | Fumapharm Ag | Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma |
| SI1799196T1 (sl) | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| MX2011001341A (es) | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| PE20141639A1 (es) | 2011-06-08 | 2014-11-08 | Biogen Idec Inc | Proceso para preparar fumarato de dimetilo de alta pureza y cristalino |
| EP2887934A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US20140057918A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
| US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| AR094277A1 (es) | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| MX386935B (es) | 2013-03-14 | 2025-03-04 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| JP2016534133A (ja) | 2013-09-06 | 2016-11-04 | ゼノポート，インコーポレイティド | （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用 |
| CN103724198A (zh) * | 2013-11-28 | 2014-04-16 | 镇江圣安医药有限公司 | 富马酸二甲酯的新型衍生物及其应用 |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| CA2939990C (en) | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| CA2965449C (en) * | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| MA40985A (fr) * | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| MA41139B1 (fr) * | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| HUE057865T2 (hu) | 2014-12-11 | 2022-06-28 | Actelion Pharmaceuticals Ltd | A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend |
| GB201907882D0 (en) | 2019-06-03 | 2019-07-17 | Cyprus Foundation For Muscular Dystrophy Res | Methods |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CN101056624A (zh) * | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| HUE032251T2 (en) * | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| EP2653873B8 (en) * | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| MX2011001341A (es) * | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| EP3318249A1 (en) * | 2009-04-29 | 2018-05-09 | Biogen MA Inc. | Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis |
-
2012
- 2012-05-25 MX MX2013013781A patent/MX2013013781A/es unknown
- 2012-05-25 US US14/119,373 patent/US20140163100A1/en not_active Abandoned
- 2012-05-25 CA CA2836480A patent/CA2836480A1/en not_active Abandoned
- 2012-05-25 PH PH1/2013/502443A patent/PH12013502443A1/en unknown
- 2012-05-25 KR KR1020137034196A patent/KR20140036257A/ko not_active Withdrawn
- 2012-05-25 SG SG2013085667A patent/SG195049A1/en unknown
- 2012-05-25 AU AU2012258558A patent/AU2012258558A1/en not_active Abandoned
- 2012-05-25 CN CN201280036988.6A patent/CN103732062A/zh active Pending
- 2012-05-25 PE PE2013002710A patent/PE20141316A1/es not_active Application Discontinuation
- 2012-05-25 WO PCT/US2012/039721 patent/WO2012162669A1/en not_active Ceased
- 2012-05-25 JP JP2014512168A patent/JP2014515373A/ja active Pending
- 2012-05-25 BR BR112013030169A patent/BR112013030169A2/pt not_active IP Right Cessation
- 2012-05-25 EA EA201391578A patent/EA201391578A1/ru unknown
- 2012-05-25 EP EP12789291.7A patent/EP2713724A4/en not_active Withdrawn
-
2013
- 2013-11-14 IL IL229448A patent/IL229448A0/en unknown
- 2013-11-19 ZA ZA2013/08681A patent/ZA201308681B/en unknown
- 2013-11-22 CL CL2013003358A patent/CL2013003358A1/es unknown
- 2013-11-26 CO CO13277997A patent/CO6811862A2/es not_active Application Discontinuation
- 2013-12-26 EC ECSP13013117 patent/ECSP13013117A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20141316A1 (es) | 2014-10-01 |
| KR20140036257A (ko) | 2014-03-25 |
| ECSP13013117A (es) | 2014-06-30 |
| WO2012162669A1 (en) | 2012-11-29 |
| CN103732062A (zh) | 2014-04-16 |
| JP2014515373A (ja) | 2014-06-30 |
| EP2713724A4 (en) | 2015-03-11 |
| IL229448A0 (en) | 2014-01-30 |
| ZA201308681B (en) | 2017-11-29 |
| EP2713724A1 (en) | 2014-04-09 |
| AU2012258558A1 (en) | 2013-05-02 |
| PH12013502443A1 (en) | 2019-03-22 |
| BR112013030169A2 (pt) | 2016-08-09 |
| CA2836480A1 (en) | 2012-11-29 |
| SG195049A1 (en) | 2013-12-30 |
| CO6811862A2 (es) | 2013-12-16 |
| US20140163100A1 (en) | 2014-06-12 |
| EA201391578A1 (ru) | 2014-05-30 |
| CL2013003358A1 (es) | 2014-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG195049A1 (en) | Methods of treating multiple sclerosis and preserving and/or increasing myelin content | |
| AU2023233141B2 (en) | Method of treatment with tradipitant | |
| ES2278393T3 (es) | Tratamiento antimicrobiano del virus herpes simplex y otras enfermedades infecciosas. | |
| AU2012321110B2 (en) | Combination treatment | |
| US10660914B2 (en) | Stuffy nose deblocking composition having antiviral activity | |
| US20210030665A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| Jampel et al. | PUVA therapy for chronic cutaneous graft-vs-host disease | |
| EP3843723B1 (en) | Composition for eradicating helicobacter pylori | |
| JP6901824B2 (ja) | 微生物により引き起こされる若しくは悪化する疾患の治療方法、又はその症状の緩和方法 | |
| EP3661490B1 (en) | Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| US20140186271A1 (en) | Reducing dental caries | |
| US11951082B2 (en) | Composition of chlorhexidine | |
| JP2016504383A (ja) | 体表面処理組成物及び処理方法 | |
| JP2026012018A (ja) | オーラノフィンを有効成分として含む腫瘍疾患予防又は治療用の薬学組成物 | |
| WO2025085050A1 (en) | Treatment of frontal fibrosing alopecia | |
| KR20120116871A (ko) | 이관개방증 치료제 | |
| US20160067187A1 (en) | Methods for Treating or Preventing Migraines | |
| HK40031502B (en) | Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis | |
| HK40031502A (en) | Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis | |
| HK40041658A (en) | Benzoic acid or a salt thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis | |
| HK1202253B (en) | Combination treatment of cancer | |
| JP2013508402A (ja) | ヘルペスウイルス感染症を治療する方法 | |
| CN104586823A (zh) | 老年斑/疣消除液 |